CN100400086C - Medicine for treating low function of ovary - Google Patents
Medicine for treating low function of ovary Download PDFInfo
- Publication number
- CN100400086C CN100400086C CNB2005101231184A CN200510123118A CN100400086C CN 100400086 C CN100400086 C CN 100400086C CN B2005101231184 A CNB2005101231184 A CN B2005101231184A CN 200510123118 A CN200510123118 A CN 200510123118A CN 100400086 C CN100400086 C CN 100400086C
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- rhizoma
- preparation
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention discloses medicine for treating hypofunction of ovary. Himalayan teasel root, barbary wolfberry fruit, angelica, desertliving cistanche, epimedium herb, common curculigo rhizome, astragalus root, rhubarb, acanthopanax, coix seed, nutgrass galingale rhizome and Chinese caterpillar fungus are used as raw materials which are decocted, extracted and prepared according to certain proportioning by weight. The medicine of the present invention can be made into any kind of common oral preparation. The medicine of the present invention has the functions of tonifying the kidney, strengthening the spleen, nourishing blood, soothing the liver, coordinating chong and conception vessels, and has the advantages of rapid effect taking, high effective rate and no toxic side effect when used for treating the hypofunction of ovary.
Description
Technical field
The present invention relates to a kind of medicine of the women's of treatment ovarian hypofunction, particularly relating to a kind of is the medicine of the treatment women ovarian hypofunction associated diseases made of raw material with the vegetable Chinese herbal medicine.
Background technology
Ovarian hypofunction is women's a common disease, from women's secondary sex characteristics grow to climacteric all have exist ovarian hypofunction may, usually show uterine hypoplasia, anovulatory is infertile, premature ovarian failure, climacteric ovarian dysfunction etc., the sickness rate of above-mentioned disease is along with the influence of factor such as environmental pollution, food pollution, drug contamination and stress be excessive, and the sickness rate of ovarian hypofunction has the trend of rising.The generation of above-mentioned disease brings injury for women's reproductive function, physical and mental health, seriously influences the female life quality, also brings negative effect to society.
At present, to the treatment of women's ovarian hypofunction, generally adopt following method and medicine both at home and abroad:
1, estrogens medicine replacement therapy can temporarily replenish the decrease in estrogen that is caused by ovarian hypofunction.But side effect is big, brings out multiple malignant diseases such as carcinoma of endometrium, breast carcinoma easily, for this reason, needs strict instructions of taking, the taking dose grasped, and brings very big inconvenience to the patient.The use of estrogens medicine is a kind of " substituting " to the patient often, uses medicine really not improve ovarian function, is a kind of method of curing the symptoms, not the disease, and long-time the use also can be suppressed ovarian function.
2, other can promote the Western medicine of ovarian function, exist side effect big equally, the problem that curative effect is single-minded inadequately, and can not take the raising of progestogen into account.As the clomiphene of clinical promotion ovulation, although can impel ovarian follicular growth, usually because of this medicine has suppressed estrogen, occur follicle maturity still can but the low drawback of pregnancy rate.
Summary of the invention
The objective of the invention is to, providing a kind of has the ovary of acting on and then improves estrogen level, treatment ovarian hypofunction, uterine hypoplasia, ovulatory dysfunction and relevant disease, and effectively alleviate, eliminate the treatment toxic and side effects that ovarian hypofunction brought, clinical a kind of novel, effective medicine and the preparation method of providing is provided.
Medicine of the present invention is a criterion with traditional Chinese medical discrimination, and the kidney invigorating takes into account spleen invigorating, and the assistant that nourishes blood is with soothing the liver, and QI invigorating is taken into account towards appointing, and in conjunction with the viewpoint of modern medicine and up-to-date herbal pharmacology research, animal experiment, has implemented the organic conception of motherland's medical science.
Medicament selection Radix Dipsaci of the present invention, Fructus Lycii, Radix Angelicae Sinensis, Herba Cistanches, Herba Epimedii, Rhizoma Curculiginis, the Radix Astragali, Radix Et Rhizoma Rhei, Radix Et Caulis Acanthopanacis Senticosi, Semen Coicis, Rhizoma Cyperi, Cordyceps carry out compatibility, each efficacy of drugs produces synergism, thereby reaches the effect of treatment women ovarian hypofunction.Radix Dipsaci liver and kidney tonifying in the side can improve the female fertility ability; The Fructus Lycii YIN nourishing and YANG strengthening, replenishing essence lengthens one's life, and there is significant effect of gain in the uterus, has the effect that promotes fertility, endocrine regulation; Chinese angelica blood supplementing is invigorated blood circulation, and is women's key medicine, to promote developing womb, to improve ovarian function useful, and also have Antiradiation injury, improve the function of immunity; The Herba Cistanches the kidney warming is strong cloudy, and the kidney invigorating and essence nourishing has the effect similar to estrogen, can promote hypophysis part cell to increase, promote the secretion of ovary progestogen, strengthen the expression of gonad axis estrogen receptor progesterone receptor, strengthen the short luteal function of hypothalamic-pituitary-ovarian; The Herba Epimedii warming and recuperating the kidney-YANG, strong muscle lengthens one's life, and all there is the growth of promotion effect in antepituitary, ovary, the uterus of animal, has significant estrogen effect; Rhizoma Curculiginis warming and recuperating the kidney-YANG, harmonizing the liver and spleen have obvious facilitation to gonad, can improve ovary hypophysis is generated plain reactivity, induced ovulation, corpus luteum are generated have tangible effect; Radix Astragali invigorating the spleen and replenishing QI has the effect that improves estrogen level; The Radix Et Rhizoma Rhei cooling blood and dissolving stasis, the detoxifcation relieving constipation can be prevented the dry of all medicines, low dose of safe and reliable, Radix Et Rhizoma Rhei has the estrogen effect, the Radix Et Caulis Acanthopanacis Senticosi replenishing QI to invigorate the spleen, tonifying the kidney for tranquilization has certain effect to endocrine regulation, raising estrogen level, promotion developing womb, can prevent spontaneous abortion again; Semen Coicis spleen invigorating eliminating dampness by diuresis can improve the hypothalamus function, has tangible effect to promoting ovulation; The Rhizoma Cyperi promoting QI circulation for relieving depression are regulated feelings will, are had significant estrogen action; The Cordyceps kidney-reinforcing Yang-strengthening, the endocrine regulation function, to estrogen level low have an obvious facilitation, and can effectively improve pregnancy rate.But all medicine combination kidney and spleen invigoratings, soothing the liver, the Chong and Ren Meridians regulating that nourishes blood effectively promote women's ovarian function, promote developing womb, keep its fertility, and estrogen, progesterone level are improved, and effectively treat the relevant disease that women's ovarian function descends and causes.
The consumption of drug component of the present invention carries out a large amount of clinical datas through the inventor gropes to sum up and draws, and each amounts of components all has better curative effect in the following weight parts scope:
Radix Dipsaci 8-24 part Fructus Lycii 12-48 part Radix Angelicae Sinensis 8-24 part
Herba Cistanches 6-24 part Herba Epimedii 14-45 part Rhizoma Curculiginis 8-24 part
Radix Astragali 8-30 part Radix Et Rhizoma Rhei 3-10 part Radix Et Caulis Acanthopanacis Senticosi 8-24 part
Semen Coicis 16-48 part Rhizoma Cyperi 8-18 part Cordyceps 3-10 part
Medicine of the present invention can adopt the conventional method of Chinese medicine preparation to be prepared into dosage form for oral administration.Medicine of the present invention can be ground into crude drug in powder and be mixed into powder, electuary, granule, oral liquid, capsule.Can get active ingredient with being condensed into decocting liquid behind each crude drug decocting; Refabrication becomes various oral agents, but these do not limit protection scope of the present invention.
Preferably the system method of medicine of the present invention is as follows:
The preparation method of described medicine, it may further comprise the steps
A) take by weighing each crude drug, standby;
B) decoct with water 5 times after Radix Dipsaci, Fructus Lycii, Radix Angelicae Sinensis, Herba Cistanches, Herba Epimedii, Rhizoma Curculiginis, the Radix Astragali, Radix Et Rhizoma Rhei, Radix Et Caulis Acanthopanacis Senticosi, Semen Coicis and the Rhizoma Cyperi 11 flavor medicine water purification flushings with described weight proportion, each amount of water was not advisable to have powder, merge 5 times decocting liquid, filter to get filtrate 1;
C) will decoct with water 5 times after the Cordyceps purification flushing, each amount of water was not advisable to have powder, merged 5 times decocting liquid, filtered to get filtrate 2;
D) filtrate 1 and filtrate 2 merging are condensed into extractum, oven dry makes dry extract in drying baker;
E) dry extract is broken into the active ingredient that powder gets medicine of the present invention.
The preparation method of described capsule, it is characterized in that active ingredient that step e) is made 110 ℃ incapsulate after the sterilization cooling in 10 minutes down capsule.
The preparation method of described tablet is characterized in that the active ingredient that step e) is made mixes with tablet adjuvant commonly used, and tabletting gets tablet.
The method of described medication preparation is characterized in that the each decocting time of step b) and step c) 30 minutes.
Medicine of the present invention shows that through clinical use result following advantage is arranged:
1, to select the edible natural plant amedica for use be raw material in the present invention, and each component meets Medicine Act regulation and tcm prescription principle, gives prominence to the dialectical characteristic that combines with differential diagnosis of diseases.
2, medicine of the present invention is made capsule through extraction, need not decoct, and good mouthfeel, taking convenience, medicine is nontoxic, and normal dose is taken and is not found any side effect of patient.
3, medicine of the present invention not only has excellent curative to women's ovarian function deficiency, and good preventing, protective effect are also arranged, and is particularly useful for taking place the women of premature ovarian failure.
4, medicine of the present invention has the clinical trial foundation, and flavour of a drug are less, and selected safety of medicine, effective does not have the estrogenic side effect of Western medicine.
The specific embodiment
Further specify effect of the present invention below in conjunction with embodiment and clinical observation.
The preparation of embodiment 1 capsule
Take by weighing raw material by following proportioning: Radix Dipsaci 10kg, Fructus Lycii 18kg, Radix Angelicae Sinensis 10kg, Herba Cistanches 12kg, Herba Epimedii 18kg, Rhizoma Curculiginis 10kg, Radix Astragali 15kg, Radix Et Rhizoma Rhei 5kg, Radix Et Caulis Acanthopanacis Senticosi 12kg, Semen Coicis 18kg, Rhizoma Cyperi 10kg, Cordyceps 5kg.
Preparation method is as follows: get Radix Dipsaci, Fructus Lycii, Radix Angelicae Sinensis, Herba Cistanches, Herba Epimedii, Rhizoma Curculiginis, the Radix Astragali, Radix Et Rhizoma Rhei, Radix Et Caulis Acanthopanacis Senticosi, Semen Coicis, Rhizoma Cyperi and put into decoction pot decoction totally 5 times jointly, decoct with water behind each extracting juice again, decocted 30 minutes at every turn.Cordyceps decocts separately, and method is the same.Fried medicine juice merged concentrate, put into the drying baker oven dry after becoming extractum, pulverize the back, sterilize 110 ℃ of insulations 10 minutes down, incapsulate standby, every dry powder 0.45g.
Embodiment 2 tablets, dissolved granule preparation
Take by weighing raw material by following proportioning: Radix Dipsaci 12kg, Fructus Lycii 15kg, Radix Angelicae Sinensis 10kg, Herba Cistanches 12kg, Herba Epimedii 15kg, Rhizoma Curculiginis 10kg, Radix Astragali 18kg, Radix Et Rhizoma Rhei 5kg, Radix Et Caulis Acanthopanacis Senticosi 15kg, Semen Coicis 24kg, Rhizoma Cyperi 10kg, Cordyceps 6kg, make medicated powder with embodiment 1 described method, be aided with tablet or electuary adjuvant commonly used again and make tablet or dissolved granule, every 0.5g, every bag of 2g of dissolved granule.
Clinical drug of the present invention is observed
One, ordinary circumstance and test method
For confirming the clinical efficacy of medicine of the present invention, year June in June, 2004-2005, the infertility that the surplus inhibition syndrome that select to have ovulation failure, estrogen progesterone reduces causes has been carried out clinical observation.The observation case is selected: menstrual cycle is normal before being oral contraceptive, amenorrhea or infrequent menstruation occur after taking contraceptive, and menstrual cycle is irregular, the ultrasound diagnosis ovary diminishes, and follicular development is immature, and no corpus luteum forms, basal body temperature is single-phase, and the estrogen progesterone level is low; Get rid of adrenal gland, pituitary tumor, abnormal thyroid function disease; Its husband's reproductive performance is normal.With the embodiment of the invention 1 Drug therapy (hereinafter to be referred as the treatment group) 52 examples, in menstrual cycle the 5th day, to take every day 3 times, each 4 capsules were taken 20 days continuously; Matched group was taken clomiphene, every day 1 time on the 5th day in menstrual cycle, each 100mg, continuous 5 days, began to take WUJI BAIFENG WAN (big ball on the 5th day in menstrual cycle simultaneously, Beijing Tongrentang produces), every day, 2 each 1 balls were taken 20 days continuously, all amenorrhea persons in two groups, inject Progesterone earlier, every day 1 time, each 20mg, logotype 3 days is to set up new menstrual cycle.27.6 ± 4.3 years old treatment group mean age in two groups, the course of disease 4.05 ± 0.81 months; 27.8 ± 2.8 years old matched group mean age, the course of disease 4.10 ± 0.87 months; Comparability (P＞0.05) is arranged between patient's mean age, the average course of disease in two groups.
Two, clinical observation standard is, recover normal through treating pregnancy or ovary size and menstrual cycle, follicular development is directly through reaching more than the 18mm, basal body temperature typical case two-phase, estrogen and progesterone level are healing normal range, menstrual cycle is normal substantially, ovary increases, have follicular development estrogen progesterone level to rise, basal body temperature is improved as effectively, and These parameters does not have improvement or the person of increasing the weight of is invalid through treating.
Three, therapeutic outcome shows, the treatment group is cured 39 examples, effective 10 examples, and invalid 3 examples, effective percentage is 96.15%; Matched group is cured 12 examples, effective 27 examples, and invalid 13 examples, effective percentage is 75.00%, by statistics with processing, both effective percentage have apparent person's property difference, P＜0.01.Treatment is organized effective patient (except that conceived person) and is carried out P2 (pregnanediol) inspection (data are mg/24 hour), means standard deviation is 1.28 ± 0.55 before the treatment, treatment back means standard deviation is 5.75 ± 0.68, shows that effective patient's progesterone level is improved.
Claims (5)
1. medicine for the treatment of ovarian hypofunction is characterized in that it is to be made by following raw medicaments in portion by weight:
Radix Dipsaci 8-24 part Fructus Lycii 12-48 part Radix Angelicae Sinensis 8-24 part
Herba Cistanches 6-24 part Herba Epimedii 14-45 part Rhizoma Curculiginis 8-24 part
Radix Astragali 8-30 part Radix Et Rhizoma Rhei 3-10 part Radix Et Caulis Acanthopanacis Senticosi 8-24 part
Semen Coicis 16-48 part Rhizoma Cyperi 8-18 part Cordyceps 3-10 part.
2. a preparation method for preparing the described medicine of claim 1 is characterized in that it may further comprise the steps
A) take by weighing each crude drug, standby;
B) decoct with water 5 times after Radix Dipsaci, Fructus Lycii, Radix Angelicae Sinensis, Herba Cistanches, Herba Epimedii, Rhizoma Curculiginis, the Radix Astragali, Radix Et Rhizoma Rhei, Radix Et Caulis Acanthopanacis Senticosi, Semen Coicis and the Rhizoma Cyperi 11 flavor medicine water purification flushings with described weight proportion, each amount of water was not advisable to have powder, merge 5 times decocting liquid, filter to get filtrate 1;
C) will decoct with water 5 times after the Cordyceps purification flushing, each amount of water was not advisable to have powder, merged 5 times decocting liquid, filtered to get filtrate 2;
D) filtrate 1 and filtrate 2 merging are condensed into extractum, oven dry makes dry extract in drying baker;
E) dry extract is broken into the active ingredient that powder gets medicine of the present invention.
3. according to the preparation method of the described medicine of claim 2, it is characterized in that active ingredient that step e) is made 110 ℃ incapsulate after the sterilization cooling in 10 minutes down capsule.
4. according to the preparation method of the described medicine of claim 2, it is characterized in that the active ingredient that step e) is made mixes with tablet adjuvant commonly used, tabletting gets tablet.
5. according to the preparation method of the described medicine of claim 2, it is characterized in that the each decocting time of step b) and step c) 30 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101231184A CN100400086C (en) | 2005-12-13 | 2005-12-13 | Medicine for treating low function of ovary |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101231184A CN100400086C (en) | 2005-12-13 | 2005-12-13 | Medicine for treating low function of ovary |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1824198A CN1824198A (en) | 2006-08-30 |
| CN100400086C true CN100400086C (en) | 2008-07-09 |
Family
ID=36935142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101231184A Expired - Fee Related CN100400086C (en) | 2005-12-13 | 2005-12-13 | Medicine for treating low function of ovary |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100400086C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181441B (en) * | 2007-11-22 | 2011-03-30 | 徐究竟 | Medicament for curing gonad progeria as well as preparation technique thereof |
| CN102716377B (en) * | 2012-06-27 | 2013-09-11 | 王忠民 | Medicament for treating ovarian hypofunction and sexual debility |
| CN108703362A (en) * | 2018-04-28 | 2018-10-26 | 广东说养自然医学技术有限公司 | A kind of nourishing ovary health care tabletting and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1596970A (en) * | 2004-07-26 | 2005-03-23 | 凌沛学 | Traditional Chinese medicament for treating woman subhealthy faligue syndrome and its preparation method |
-
2005
- 2005-12-13 CN CNB2005101231184A patent/CN100400086C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1596970A (en) * | 2004-07-26 | 2005-03-23 | 凌沛学 | Traditional Chinese medicament for treating woman subhealthy faligue syndrome and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1824198A (en) | 2006-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103169881B (en) | Chinese medicament health product for supplementing female hormone for women during menopause and preparation method thereof | |
| Gao et al. | Study of osteoporosis treatment principles used historically by ancient physicians in Chinese Medicine | |
| CN101954037B (en) | Chinese medicinal preparation for treating prostatitis | |
| CN101380440A (en) | Use of Yunkang oral liquid in preparing medicine for treating kidney-deficiency type sterility | |
| CN103386008A (en) | Chinese medicine composition for treating endocrine dyscrasia | |
| CN104547579A (en) | Medicine composition for treating hyperprolactinemia infertility and application of medicine composition | |
| CN104984297A (en) | Application of pharmaceutical composition in preparation of drugs for treating amenorrhea | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN1806840B (en) | Chinese medicinal compound preparation and its preparing process | |
| CN101269170B (en) | Medicament for treating climacteric syndrome and preparation method thereof | |
| CN101543622B (en) | Chinese medicament series for treating anovulatory infertility | |
| CN106362104A (en) | Pharmaceutical composition for treating polycystic ovary syndrome in adolescence | |
| CN100400086C (en) | Medicine for treating low function of ovary | |
| CN101138597B (en) | Traditional Chinese medicine preparation for preventing and controlling osteoporosis and method of preparing the same | |
| CN103933294B (en) | A kind of plant extract compositions for sexual dysfunction | |
| CN103330837B (en) | Traditional Chinese medicine composition for curing osteoporosis of menopausal women | |
| CN110201122B (en) | Traditional Chinese medicine composition for treating irregular menstruation and preparation method and application thereof | |
| CN113398223A (en) | Traditional Chinese medicine composition, powder and pill for treating infertility and preparation method and application thereof | |
| CN105288538A (en) | Application of medicine composition for preparing medicine for treating amenorrhea | |
| CN104352994A (en) | Pharmaceutical preparation for sexual dysfunction | |
| CN100509019C (en) | Application of Baji capsule in preparing immune enhancement medicament | |
| CN103816336A (en) | Formula of Yugongpeilin pill and preparation process | |
| CN104324186A (en) | Traditional Chinese medicine prescription for treating climacteric syndrome, and preparation methods of capsule and ointment of traditional Chinese medicine prescription | |
| CN104491677A (en) | Preparation method of medicament for treating sexual dysfunction | |
| CN106540168B (en) | Traditional Chinese medicine composition for treating kidney deficiency type irregular menstruation, amenorrhea and infertility as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080709 Termination date: 20121213 |